Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Evercore HealthCONx Conference Transcript

Dec 04, 2019 / 06:15PM GMT
Release Date Price: $121.98 (-0.32%)
Ravindra Mehrotra
Evercore ISI Institutional Equities, Research Division - Senior MD

Okay. Good afternoon, everyone. My name is Ravi Mehrotra. I'm a senior biotech analyst at Evercore ISI. It gives me great pleasure to have (inaudible) Jeff, President and CFO from Alnylam.

I have personally been looking forward to this fireside chat over all the 20 others that I've given, because Alnylam is a company which fits the most into our M2 thesis, which I'm sure most of you heard me talk about, and really trailblazed it for everyone else. We've now broken these down to Generation 1 and Generation 2. People forget just how long you guys have been doing this. So we're going to mix this fireside chat up a little bit. We're definitely going to talk about the assets, and we'll come on to some of the financial things. But I really want to start with this concept of M2. And (inaudible) really open to both of you to say, and you can criticize the thesis as much as you want or you can validate it as much as you want, but certainly, in my eyes, the modality is obvious. You were a pioneer in RNAi. The modularity

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot